The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1367
Spinosad (Natroba) Topical Suspension for Head Lice
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved spinosad 0.9% suspension (Natroba – ParaPro) for topical treatment of head lice infestation in patients ≥4 years old. It is available only by prescription.

MECHANISM OF ACTION — Spinosad is a fermentation product of the soil actinomycete Saccharopolyspora spinosa. It causes neuronal excitation in insects, leading to paralysis and death. It is not ovicidal. Natroba contains an unspecified amount of benzyl alcohol, which is also pediculicidal.1

PHARMACOKINETICS — An unpublished study in 14 children with head lice summarized in the package insert found that application of spinosad 0.18% for 10 minutes did not produce detectable plasma levels of the drug. Plasma concentrations of benzyl alcohol were not determined.

DRUGS FOR HEAD LICEPyrethrins ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Spinosad (Natroba) Topical Suspension for Head Lice
Article code: 1367b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian